Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DIVYANSU PATEL

Allopathic & Osteopathic Physicians Psychiatry & Neurology Psychiatry

NPI
1710178702
CMS profile
31895
Location
AUSTIN, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$3,627.93

232 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $3,627.93 232

By paying entity

PY2023 · entire year · sorted by reported total

Page 3 of 5; records 101–150 of 232 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DIVYANSU PATEL

NPI 1710178702 · CMS profile ID 31895

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Psychiatry

AUSTIN, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 5; records 101–150 of 232 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1710178702?year=2023&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DIVYANSU PATEL, NPI 1710178702, CMS profile ID 31895. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 232 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1710178702?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). DIVYANSU PATEL, NPI 1710178702, CMS profile ID 31895. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 232 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1710178702?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
DIVYANSU PATEL, NPI 1710178702, CMS profile ID 31895, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 5; records 101–150 of 232 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1710178702?year=2023&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

232 matching records · $3,627.93 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 232 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 232.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Alkermes, Inc. $17.3405/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022892097 CMS
Supernus Pharmaceuticals, Inc. $0.1705/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053294339 CMS
Otsuka America Pharmaceutical, Inc. $19.9005/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014674881 CMS
Supernus Pharmaceuticals, Inc. $3.2105/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053294331 CMS
Supernus Pharmaceuticals, Inc. $3.3505/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053294335 CMS
Supernus Pharmaceuticals, Inc. $0.4005/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053294327 CMS
Alkermes, Inc. $25.3205/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022892095 CMS
Alkermes, Inc. $0.1605/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022892089 CMS
Alkermes, Inc. $1.2005/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022892091 CMS
Alkermes, Inc. $1.8805/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022892093 CMS
Tris Pharma Inc $31.0705/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059335961 CMS
Supernus Pharmaceuticals, Inc. $0.7705/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053294323 CMS
Janssen Scientific Affairs, LLC $109.8005/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988761465 CMS
Otsuka America Pharmaceutical, Inc. $3.7605/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014674867 CMS
Neurocrine Biosciences, Inc. $41.0705/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1052123883 CMS
Otsuka America Pharmaceutical, Inc. $2.4005/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014674857 CMS
Tris Pharma Inc $12.7305/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059335957 CMS
IDORSIA PHARMACEUTICALS US INC $9.7105/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1038239995 CMS
Otsuka America Pharmaceutical, Inc. $18.9305/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014674845 CMS
Tris Pharma Inc $113.3405/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059335963 CMS
ABBVIE INC. $10.3005/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998085763 CMS
ABBVIE INC. $26.5905/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998085765 CMS
Supernus Pharmaceuticals, Inc. $0.9105/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053294319 CMS
ITI, Inc. $6.8305/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040651927 CMS
ITI, Inc. $11.4305/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040651917 CMS
Supernus Pharmaceuticals, Inc. $3.0405/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053294315 CMS
Janssen Pharmaceuticals, Inc $18.5005/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988643755 CMS
ABBVIE INC. $100.0005/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998085761 CMS
CSL Behring $26.4505/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1043065487 CMS
Corium, LLC $18.5405/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 978200309 CMS
Lundbeck LLC $29.9205/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032311729 CMS
Supernus Pharmaceuticals, Inc. $3.3804/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053294311 CMS
ABBVIE INC. $19.7904/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998085759 CMS
Supernus Pharmaceuticals, Inc. $3.1504/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053294307 CMS
Supernus Pharmaceuticals, Inc. $0.9804/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053294303 CMS
Tris Pharma Inc $25.2404/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059335953 CMS
Tris Pharma Inc $17.1204/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059335951 CMS
Corium, LLC $12.7604/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 978200317 CMS
Ironshore Pharmaceuticals Inc. $16.4704/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060506057 CMS
Teva Pharmaceuticals USA, Inc. $121.3804/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056744405 CMS
Otsuka America Pharmaceutical, Inc. $18.4004/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014674833 CMS
ABBVIE INC. $19.0004/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998085757 CMS
Alkermes, Inc. $21.2904/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022892087 CMS
Tris Pharma Inc $13.3004/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059335945 CMS
Tris Pharma Inc $5.2204/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059335943 CMS
Lundbeck LLC $12.8404/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032311721 CMS
Tris Pharma Inc $8.1004/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059335939 CMS
Tris Pharma Inc $16.8404/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059335935 CMS
Corium, LLC $19.9004/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 978200301 CMS
Tris Pharma Inc $13.1904/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059335937 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $29,269.63 236
PY2020 $4,362.46 191
PY2021 $4,802.01 268
PY2022 $3,958.02 243
PY2023 $3,627.93 232
PY2024 $1,998.54 99
PY2025 $1,765.13 52

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $246,600.08 64
PY2024 Principal investigator $559,025.93 91
PY2023 Principal investigator $192,303.75 38
PY2022 Principal investigator $398,358.73 81
PY2021 Principal investigator $513,813.14 156
PY2020 Principal investigator $515,203.66 153
PY2019 Recipient $96,274.79 36
PY2019 Principal investigator $366,157.13 69

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

64 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $1,699.68 12/31/2025 Non-covered Recipient Entity
BIOBEHAVIORAL RESEARCH OF AUSTIN
A 52-Week, Multicenter, Open-Label, Flexible-dose Study to Evaluate the Long-term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Subjects with Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder No dispute reported 06/30/2026 1202532534
Principal investigator 1 ABBVIE INC. $274.92 12/31/2025 Non-covered Recipient Entity
BIOBEHAVIORAL RESEARCH OF AUSTIN
A 6-week, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Efficacy and Safety of Cariprazine in Pediatric Subjects (10 to 17 years of age) in the Treatment of Depressive Episodes Associated with Bipolar I Disorder No dispute reported 06/30/2026 1202532536
Principal investigator 1 ABBVIE INC. $240.00 12/31/2025 Non-covered Recipient Entity
BIOBEHAVIORAL RESEARCH OF AUSTIN
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Single-attack Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral Ubrogepant in the Acute Treatment of Migraine With or Without Aura in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202533909
Principal investigator 1 PFIZER INC. $923.42 12/24/2025 Non-covered Recipient Entity
Biobehavioral Research Of Austin PC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228811615
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,247.87 12/09/2025 Non-covered Recipient Entity
BIOBEHAVIORAL RESEARCH OF AUSTIN PC
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder Who Have an Inadequate Response to Generalized Anxiety Disorder Treatment No dispute reported 06/30/2026 1242369081
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,400.00 11/19/2025 Non-covered Recipient Entity
BIOBEHAVIORAL RESEARCH OF AUSTIN
ITI-007-421 No dispute reported 06/30/2026 1242366145
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $15,684.97 11/10/2025 Non-covered Recipient Entity
BIOBEHAVIORAL RESEARCH OF AUSTIN PC
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder Who Have an Inadequate Response to Generalized Anxiety Disorder Treatment No dispute reported 06/30/2026 1242365931
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $324.72 11/10/2025 Non-covered Recipient Entity
BIOBEHAVIORAL RESEARCH OF AUSTIN PC
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder Who Have an Inadequate Response to Generalized Anxiety Disorder Treatment No dispute reported 06/30/2026 1242365933
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $300.01 11/06/2025 Non-covered Recipient Entity
BIOBEHAVIORAL RESEARCH OF AUSTIN
ITI-007-602 No dispute reported 06/30/2026 1242365839
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $108.57 11/06/2025 Non-covered Recipient Entity
BIOBEHAVIORAL RESEARCH OF AUSTIN
ITI-007-602 No dispute reported 06/30/2026 1242365859
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $89.53 11/03/2025 Non-covered Recipient Entity
BIOBEHAVIORAL RESEARCH OF AUSTIN
ITI-007-421 No dispute reported 06/30/2026 1242365279
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,500.00 10/13/2025 Non-covered Recipient Entity
BIOBEHAVIORAL RESEARCH OF AUSTIN
ITI-007-421 No dispute reported 06/30/2026 1242363749
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $16,514.75 10/06/2025 Non-covered Recipient Entity
BIOBEHAVIORAL RESEARCH OF AUSTIN PC
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder Who Have an Inadequate Response to Generalized Anxiety Disorder Treatment No dispute reported 06/30/2026 1242363347
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $8,122.44 10/06/2025 Non-covered Recipient Entity
BIOBEHAVIORAL RESEARCH OF AUSTIN PC
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder Who Have an Inadequate Response to Generalized Anxiety Disorder Treatment No dispute reported 06/30/2026 1242363355
Principal investigator 1 Janssen Research & Development, LLC $5,581.00 09/12/2025 Non-covered Recipient Entity
BIOBEHAVIORAL RESEARCH OF AUSTIN PC
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso No dispute reported 06/30/2026 1175373940
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $8,277.25 09/08/2025 Non-covered Recipient Entity
BIOBEHAVIORAL RESEARCH OF AUSTIN PC
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder Who Have an Inadequate Response to Generalized Anxiety Disorder Treatment No dispute reported 06/30/2026 1242358618
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $438.82 08/25/2025 Non-covered Recipient Entity
BIOBEHAVIORAL RESEARCH OF AUSTIN
ITI-007-602 No dispute reported 06/30/2026 1242358154
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $363.34 08/25/2025 Non-covered Recipient Entity
BIOBEHAVIORAL RESEARCH OF AUSTIN
ITI-007-602 No dispute reported 06/30/2026 1242358156
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $883.46 08/20/2025 Non-covered Recipient Entity
BIOBEHAVIORAL RESEARCH OF AUSTIN
ITI-007-602 No dispute reported 06/30/2026 1242357598
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $661.83 08/11/2025 Non-covered Recipient Entity
BIOBEHAVIORAL RESEARCH OF AUSTIN PC
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder Who Have an Inadequate Response to Generalized Anxiety Disorder Treatment No dispute reported 06/30/2026 1242356898
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $9,500.00 07/25/2025 Non-covered Recipient Entity
BIOBEHAVIORAL RESEARCH OF AUSTIN
ITI-007-321 No dispute reported 06/30/2026 1242355444
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,200.00 06/19/2025 Non-covered Recipient Entity
Biobehavioral Research Of Austin
An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in De Novo Subjects With DSM-5 Schizophrenia No dispute reported 06/30/2026 1235998666
Principal investigator 1 Janssen Research & Development, LLC $4,303.75 06/16/2025 Non-covered Recipient Entity
BIOBEHAVIORAL RESEARCH OF AUSTIN PC
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso No dispute reported 06/30/2026 1175373948
Principal investigator 1 ABBVIE INC. $3,979.00 06/03/2025 Non-covered Recipient Entity
BIOBEHAVIORAL RESEARCH OF AUSTIN
Open-Label Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1202488201
Principal investigator 1 ABBVIE INC. $1,850.00 05/22/2025 Non-covered Recipient Entity
BIOBEHAVIORAL RESEARCH OF AUSTIN
Open-Label Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1202485891
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $5,650.00 05/14/2025 Non-covered Recipient Entity
BIOBEHAVIORAL RESEARCH OF AUSTIN
ITI-007-602 No dispute reported 06/30/2026 1242347448
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $800.00 05/14/2025 Non-covered Recipient Entity
BIOBEHAVIORAL RESEARCH OF AUSTIN
ITI-007-602 No dispute reported 06/30/2026 1242347450
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $500.00 05/14/2025 Non-covered Recipient Entity
BIOBEHAVIORAL RESEARCH OF AUSTIN
ITI-007-602 No dispute reported 06/30/2026 1242347452
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,000.00 05/14/2025 Non-covered Recipient Entity
BIOBEHAVIORAL RESEARCH OF AUSTIN
ITI-007-602 No dispute reported 06/30/2026 1242347454
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,000.00 05/14/2025 Non-covered Recipient Entity
BIOBEHAVIORAL RESEARCH OF AUSTIN
ITI-007-602 No dispute reported 06/30/2026 1242347456
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,000.00 05/14/2025 Non-covered Recipient Entity
BIOBEHAVIORAL RESEARCH OF AUSTIN
ITI-007-602 No dispute reported 06/30/2026 1242347458
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $9,500.00 05/14/2025 Non-covered Recipient Entity
BIOBEHAVIORAL RESEARCH OF AUSTIN
ITI-007-602 No dispute reported 06/30/2026 1242347460
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $500.00 05/14/2025 Non-covered Recipient Entity
BIOBEHAVIORAL RESEARCH OF AUSTIN
ITI-007-602 No dispute reported 06/30/2026 1242347462
Principal investigator 1 ABBVIE INC. $15,794.00 05/06/2025 Non-covered Recipient Entity
BIOBEHAVIORAL RESEARCH OF AUSTIN
Open-Label Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1202481851
Principal investigator 1 ABBVIE INC. $3,050.00 04/16/2025 Non-covered Recipient Entity
BIOBEHAVIORAL RESEARCH OF AUSTIN
A Study of the Change in Disease State and Safety of Oral Cariprazine Capsules in the Treatment of Depression in Pediatric Participants (10 to 17 Years of Age) With Bipolar I Disorder No dispute reported 06/30/2026 1202476847
Principal investigator 1 ABBVIE INC. $90.00 04/08/2025 Non-covered Recipient Entity
BIOBEHAVIORAL RESEARCH OF AUSTIN INC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202474833
Principal investigator 1 ABBVIE INC. $14,790.00 04/03/2025 Non-covered Recipient Entity
BIOBEHAVIORAL RESEARCH OF AUSTIN
Open-Label Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1202468945
Principal investigator 1 ABBVIE INC. $225.00 03/24/2025 Non-covered Recipient Entity
BIOBEHAVIORAL RESEARCH OF AUSTIN
Open-Label Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1202465533
Principal investigator 1 ABBVIE INC. $7,750.00 03/19/2025 Non-covered Recipient Entity
BIOBEHAVIORAL RESEARCH OF AUSTIN
M21-465 - Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD No dispute reported 06/30/2026 1202464367
Principal investigator 1 ABBVIE INC. $1,000.00 03/13/2025 Non-covered Recipient Entity
BIOBEHAVIORAL RESEARCH OF AUSTIN INC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202463567
Principal investigator 1 ABBVIE INC. $978.75 03/13/2025 Non-covered Recipient Entity
BIOBEHAVIORAL RESEARCH OF AUSTIN
M21-465 - Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD No dispute reported 06/30/2026 1202463585
Principal investigator 1 PFIZER INC. $2,200.00 03/13/2025 Non-covered Recipient Entity
Biobehavioral Research Of Austin PC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228822084
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $800.00 03/10/2025 Non-covered Recipient Entity
BIOBEHAVIORAL RESEARCH OF AUSTIN
ITI-007-421 No dispute reported 06/30/2026 1242335040
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $500.00 03/10/2025 Non-covered Recipient Entity
BIOBEHAVIORAL RESEARCH OF AUSTIN
ITI-007-421 No dispute reported 06/30/2026 1242335042
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $500.00 03/10/2025 Non-covered Recipient Entity
BIOBEHAVIORAL RESEARCH OF AUSTIN
ITI-007-421 No dispute reported 06/30/2026 1242335096
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,000.00 03/10/2025 Non-covered Recipient Entity
BIOBEHAVIORAL RESEARCH OF AUSTIN
ITI-007-421 No dispute reported 06/30/2026 1242335098
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,000.00 03/10/2025 Non-covered Recipient Entity
BIOBEHAVIORAL RESEARCH OF AUSTIN
ITI-007-421 No dispute reported 06/30/2026 1242335100
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,000.00 03/10/2025 Non-covered Recipient Entity
BIOBEHAVIORAL RESEARCH OF AUSTIN
ITI-007-421 No dispute reported 06/30/2026 1242335102
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $9,500.00 03/10/2025 Non-covered Recipient Entity
BIOBEHAVIORAL RESEARCH OF AUSTIN
ITI-007-421 No dispute reported 06/30/2026 1242335104
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $800.00 03/07/2025 Non-covered Recipient Entity
BIOBEHAVIORAL RESEARCH OF AUSTIN
ITI-007-421 No dispute reported 06/30/2026 1242334776
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $500.00 03/07/2025 Non-covered Recipient Entity
BIOBEHAVIORAL RESEARCH OF AUSTIN
ITI-007-421 No dispute reported 06/30/2026 1242334778
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $500.00 03/07/2025 Non-covered Recipient Entity
BIOBEHAVIORAL RESEARCH OF AUSTIN
ITI-007-421 No dispute reported 06/30/2026 1242334780
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,000.00 03/07/2025 Non-covered Recipient Entity
BIOBEHAVIORAL RESEARCH OF AUSTIN
ITI-007-421 No dispute reported 06/30/2026 1242334782
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,000.00 03/07/2025 Non-covered Recipient Entity
BIOBEHAVIORAL RESEARCH OF AUSTIN
ITI-007-421 No dispute reported 06/30/2026 1242334784
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,000.00 03/07/2025 Non-covered Recipient Entity
BIOBEHAVIORAL RESEARCH OF AUSTIN
ITI-007-421 No dispute reported 06/30/2026 1242334786
Principal investigator 1 ABBVIE INC. $8,904.00 03/06/2025 Non-covered Recipient Entity
BIOBEHAVIORAL RESEARCH OF AUSTIN
Open-Label Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1202458283
Principal investigator 1 ABBVIE INC. $568.00 02/20/2025 Non-covered Recipient Entity
BIOBEHAVIORAL RESEARCH OF AUSTIN
Open-Label Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1202453198
Principal investigator 1 Janssen Research & Development, LLC $12,786.00 02/03/2025 Non-covered Recipient Entity
BIOBEHAVIORAL RESEARCH OF AUSTIN PC
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso No dispute reported 06/30/2026 1175373927
Principal investigator 1 Janssen Research & Development, LLC $36,750.00 01/22/2025 Non-covered Recipient Entity
BIOBEHAVIORAL RESEARCH OF AUSTIN PC
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso No dispute reported 06/30/2026 1175373931
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,200.00 01/21/2025 Non-covered Recipient Entity
BIOBEHAVIORAL RESEARCH OF AUSTIN
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder Who Have an Inadequate Response to Generalized Anxiety Disorder Treatment No dispute reported 06/30/2026 1242328711
Principal investigator 1 ABBVIE INC. $225.00 01/09/2025 Non-covered Recipient Entity
BIOBEHAVIORAL RESEARCH OF AUSTIN
Open-Label Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1202437776
Principal investigator 1 ABBVIE INC. $850.00 01/08/2025 Non-covered Recipient Entity
BIOBEHAVIORAL RESEARCH OF AUSTIN
Open-Label Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1202437266
Principal investigator 1 ABBVIE INC. $1,320.00 01/07/2025 Non-covered Recipient Entity
BIOBEHAVIORAL RESEARCH OF AUSTIN
M21-465 - Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD No dispute reported 06/30/2026 1202437050
Principal investigator 1 ABBVIE INC. $3,600.00 01/02/2025 Non-covered Recipient Entity
BIOBEHAVIORAL RESEARCH OF AUSTIN
M21-465 - Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD No dispute reported 06/30/2026 1202435773